Over-the-Counter CGMs: Stelo, Lingo, and Libre Rio, No Prescription Needed

You've wondered for months what your blood sugar actually does: after the pasta, during the 3pm slump, overnight. Your doctor said your numbers are "borderline," or you have type 2 managed with pills and no one ever offered you a sensor, or you have no diagnosis at all and you're just curious. Until recently the answer was a prescription, a prior authorization, and a fight. Since 2024 there's a second door: over-the-counter CGMs you can order today with a credit card and no prescription.

Three products define the category. The FDA cleared Dexcom's Stelo in March 2024 as the first over-the-counter CGM, cleared for adults 18 and older who don't use insulin. Abbott followed with two: Lingo, aimed at general health and metabolic curiosity with no diabetes diagnosis needed, and Libre Rio, cleared for adults with type 2 diabetes who don't use insulin. All three are the same core technology as their prescription siblings: a small sensor on the back of the arm, a filament under the skin, readings to your phone for about two weeks per sensor.

Who are OTC CGMs designed for?

• Type 2 diabetes managed without insulin. Orals like metformin, diet and exercise. Commercial coverage for prescription CGMs is thinnest for exactly this group, so the OTC lane was built for you. Seeing what meals and walks do to your glucose is genuinely useful feedback to bring to your care team.
• Prediabetes. If you've been told you're in the reversal window, a few sensor cycles can show which habits move your numbers, while the window is still open.
• The health-curious with no diagnosis. Athletes, biohackers, people with a family history who want a preview. Legitimate use, with expectations worth calibrating (more below).
• People priced out of the prescription channel. If your plan denied a prescription CGM or the coinsurance is brutal, OTC cash pricing may simply be the cheaper door (more below too).

What do over-the-counter CGMs cost?

All three sell subscription-style, direct from the maker's site or at pharmacies, and as of this writing the practical range is roughly $50 to $100 a month depending on product and plan: Stelo runs near the top of that range month-to-month with discounts on longer subscriptions, and Lingo sells single sensors and multi-week plans that land in the same band. Prices shift, so check the maker's site before you commit. Two cost notes that surprise people: OTC CGMs are generally FSA/HSA eligible, which discounts them by your marginal tax rate, and no insurance means no deductible math, no prior auth, and no pharmacy-versus-DME channel maze. The price on the site is the price.

How do they differ from prescription Dexcom G7 and Libre 3?

• Alarms. This is the big one. Prescription CGMs fire urgent alerts for dangerous lows, including the overnight lows insulin users fear. OTC sensors surface trends and gentle notifications; they are built for people whose medications don't cause severe hypoglycemia.
• Indication. Prescription CGMs are cleared to inform treatment decisions, including insulin dosing. OTC CGMs are cleared for awareness and education in non-insulin users, and their FDA clearance says so explicitly.
• Integrations. Prescription sensors talk to insulin pumps and automated delivery systems. OTC sensors talk to their own apps.
• Reading cadence and display. OTC apps smooth and summarize (Stelo, for example, updates in batched intervals) where prescription apps stream every reading with tighter real-time urgency.
• The paperwork. Prescription CGMs need a prescriber, often a prior auth, and sometimes a letter of medical necessity. OTC needs a checkout page.

The insurance angle: when OTC beats the coverage fight

If you have type 2 without insulin, plans deny prescription CGM coverage more often than for any other group, and list price on prescription sensors without coverage runs well above OTC pricing. Two moves follow. First, the simple one: an OTC CGM can be cheaper than a prescription CGM your plan won't cover, full stop, with zero paperwork. Second, the chess move: a few weeks of OTC sensor data showing real patterns (post-meal spikes, morning highs, swings your fingersticks never caught) can become documented evidence in your chart that supports a prescription CGM prior auth or appeal later. Wear the cheap sensor, bring the data to your clinician, and let it strengthen the case for the covered one.

Honest expectations, especially without diabetes

If you don't have diabetes, expect your glucose to be mostly unremarkable, and expect the app to make ordinary physiology feel dramatic. Healthy people spike after carbs; that is glucose working. Sensors also have quirks: readings lag blood by several minutes, day-one data runs noisy, and sleeping on the sensor can print false lows. The useful frame is patterns over points: a consistent morning rise, a meal that reliably spikes you, the same meal behaving differently on different days. Those patterns are conversation material for a clinician, who can read them against your labs and history. What the data is not: a diagnosis, a grade, or a license to overhaul medications or slash whole food groups on your own.